Biomarkers in psychiatry should be a wake‑up call about missed physical illness, not a green light to double down on labeling people “mentally ill” while their bodies are quietly failing.

A story psychiatry should not ignore

The USA Today piece opens with a chilling example: a pregnant neuroscientist whose “postpartum depression” did not budge after four antidepressants and two antipsychotics, but improved within hours once an autoimmune disease, lupus, was finally diagnosed and treated. That case is not evidence that psychiatry just needs better biomarkers; it is evidence that physicians repeatedly treated a brain as if it were disconnected from the body, while a serious physical illness went undetected.

Psychiatrists in the article hail the American Psychiatric Association’s new enthusiasm for blood tests, immune markers and brain‑based diagnostics as “the beginning of a revolution.” But the true revolution is far more basic: stop calling people mentally ill when they are, in fact, physically sick, and stop using a psychiatric label as the end of the diagnostic journey instead of the beginning.

Biomarkers: proof of biology, not proof of “mental disorder”

The article cites C‑reactive protein and other inflammatory markers as potential guides for choosing psychiatric drugs, suggesting they might predict who responds better to dopamine‑targeting medications versus SSRIs. Even if those associations replicate, they show what non‑psychiatric medical doctors have warned for decades: inflammation, autoimmunity, endocrine disruption and other bodily processes can drive distress, fatigue, cognitive changes and mood symptoms that get coded as “major depression” or “bipolar disorder.”

Biological signals in blood are not uniquely “psychiatric biomarkers”; they are general medical red flags that should trigger deeper investigation of cardiovascular, autoimmune, infectious, metabolic and neurological disease. When the profession rushes to interpret these markers primarily as refinements of DSM labels, it risks institutionalizing a dangerous error: reading the body’s cry for medical help as justification for more psychotropic drugs rather than for comprehensive medical work‑ups and non‑drug interventions.

The deadly cost of diagnostic short‑cuts

Research already documents what families see every day: people with psychiatric labels die dramatically younger than their peers, often by 10–20 years, and the bulk of these excess deaths are due to ordinary physical diseases like heart disease, stroke, respiratory illness and cancer. Multiple reviews have warned that clinicians frequently attribute physical complaints to an underlying diagnosis of “mental illness,” leading to missed or delayed detection of treatable medical conditions.

In other words, the system does not merely fail to recognize physical illness; it systematically trains providers to see psychiatric labels first and the rest of the body second, or not at all. In this context, framing biomarkers primarily as tools for more precise psychiatric drugging ignores the central scandal: people are dying early because their physical health problems are not being properly screened, investigated or treated once a mental health code is in their chart.

The DSM is not a substitute for a stethoscope

The American Psychiatric Association now openly contemplates weaving biomarkers into the next edition of the DSM, “psychiatry’s bible.” That move would cement a model in which lab findings are interpreted through the lens of symptom clusters, not through a full internal medicine work‑up that asks the most basic questions: What is happening in this person’s immune system? Endocrine system? Nervous system? Cardiovascular system?

The pregnant scientist profiled did not need a more sophisticated DSM code; she needed a clinician who saw her depressive symptoms as potential signs of systemic autoimmunity rather than as isolated “mental illness.” Families know that when primary care and specialty medicine are sidelined in favor of quick psychiatric labeling, serious conditions, from thyroid disease to epilepsy to lupus, can be missed until irreversible damage has been done.

Follow the biomarkers all the way to real medicine

If biomarkers have any hope of improving lives, they must be used as levers to expand, not contract, genuine medical investigation. That means:

• Requiring comprehensive physical exams, lab panels and appropriate imaging before attaching long‑term psychiatric labels, especially in children and pregnant or postpartum women.
• Training all physicians, not just psychiatrists, that inflammation, autoimmunity, infection and metabolic dysfunction routinely masquerade as “mental” disorders and must be ruled out, not assumed away.
• Building integrated clinics where internal medicine, neurology, immunology and psychiatry collaborate, and where abnormal biomarkers trigger referrals to non‑psychiatric specialists, not only to psychopharmacology consults.

Used this way, biomarkers would vindicate what many non‑psychiatric doctors have been saying: the mind’s distress is often the body’s first alarm. Listen to the alarm, and you may prevent not just years of suffering under the wrong label, but the quietly shortened lives that have become the grim hallmark of our current system.